mTOR-inhibitors may aggravate chronic hepatitis E  by Debing, Yannick & Neyts, Johan
EditorialmTOR-inhibitors may aggravate chronic hepatitis E
Yannick Debing, Johan Neyts⇑
Rega Institute for Medical Research, Department of Microbiology and Immunology, University of Leuven,
Minderbroedersstraat 10, 3000 Leuven, BelgiumSee Article, pages 746–754Althoughhepatitis E virus (HEV) is amuchunderstudied pathogen,
it is one of themost important causes of acute hepatitisworldwide.
Based on calculations for genotypes 1 and 2, an annual incidence of
20 million HEV infections resulting in about 70,000 deaths has
been estimated [1]. These twogenotypes are endemic indeveloping
countries and cause large-scale water-borne outbreaks [2], such as
the very recent outbreak in Nepal (www.promedmail.org; archive
number: 20140509.2461705). A hallmark for such outbreaks is
the high morbidity and mortality observed in pregnant women,
with fatality rates up to 25%. The underlying pathogenesis for this
particular vulnerability of pregnant woman is only very poorly
understood [1–3], although progesterone receptor polymorphisms
may play a role [4]. Genotypes 3 and 4 are, by contrast, zoonotic
pathogens that are frequently detected in commercial pig herds,
but also in wild boar and deer [2,3]. The consumption of un- or
undercooked pork is, as consequence, a major risk factor for
contracting hepatitis E. Accordingly, the south of France is consid-
ered to be a hyperendemic region because of the popularity of local
delicacies, such as ﬁgatellu, that are prepared with raw pork [3,5].
In general, most HEV infections are asymptomatic and most
symptomatic infections resolve spontaneously [2,3]. Nevertheless,
some patients may evolve to fulminant hepatitis, explaining the
reported overall mortality rates of 0.5–4% [3]. Since 2008, it is
knownthat hepatitis E can evolve to chronicity in immunocompro-
mised patients [6]. Chronic hepatitis E has since been observed in
HIVpatients and leukemiapatients undergoing chemotherapy, but
most cases are organ transplant recipients receiving immunosup-
pressive treatment [2]. About 30% of chronic infections in the latter
group canbe resolvedby reducing the level of immunosuppression
[7]. Commonly used immunosuppressive drugs in the transplant
setting are corticosteroids, mycophenolate mofetil (MMP), calci-
neurin inhibitors (cyclosporin A and tacrolimus) and the mTOR
(mammalian target of rapamycin) inhibitors such as rapamycin
and everolimus. In this issue of the Journal of Hepatology, Zhou
et al. demonstrate that the latter two drugs promote in vitro HEVJournal of Hepatology 20
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Open access under CC BY-NC-ND license.replication through inhibition of mTOR [8]. Thorough studies of
the involved signalling pathways reveal that mTOR is part of an
antiviral signalling pathway that inhibits HEV replication. This
antiviral activity is mediated through the eIF4E-binding protein 1
(4E-BP1) directly downstream of mTOR.
In another recent study by the same authors, the in vitro effect
of other immunosuppressive drugs on HEV replication was
reported [9]. While steroids were shown to have no effect on viral
replication, the calcineurin targeting drugs cyclosporin A and
tacrolimus resulted in a pronounced proviral effect, which was
shown to be mediated by the inhibition of cyclophilins A and B.
By contrast, mycophenolic acid (the active component of myco-
phenolate mofetil, MMP) was shown to be an inhibitor of
in vitro HEV replication [9,10]. This antiviral effect may be in line
with a clinical observation that the use of MMP was associated
with HEV clearance [11]. It should be noted though that this
observation was based on a small number of patients.
These ﬁndings raise the question whether the immunosup-
pressive drug scheme should be adapted for patients with chronic
hepatitis E. Should calcineurin and mTOR inhibitors be avoided
and MMP (and possibly steroids) be preferred if a patient in need
of immunosuppression has been shown to be HEV positive?
Should such preferences be extended to non-infected patients
who are at risk of contracting chronic hepatitis E (such as for
example pig farmers)? One important caveat is that such recom-
mendations would be solely based on in vitro ﬁndings that possi-
bly do not take all aspects of hepatitis E pathogenesis into account.
For instance, the in vitro anti-HEV activity of mycophenolic acid is
mediated by an efﬁcient depletion of intracellular GTP pools in
cell cultures; an antiviral effect that can be easily reversed upon
exogenously addition of guanosine [10]. It is however question-
able whether such strong depletion of GTP pools by MMF is at
all possible in the human liver [12]. Even if MMF would be able
to deplete GTP pools in the liver to levels that may be sufﬁciently
low to impact HEV replication, the virus may, in an immunocom-
promised environment, not necessarily bemuch limited in its rep-
lication. Mycophenolic acid inhibits also efﬁciently and
completely the in vitro replication of a number of ﬂaviviruses
[13]. Yet in a murine model for ﬂavivirus infection, we did not
observe any protective activity of MMF (our unpublished data).
Similarly, addition of MMF to interferon for the treatment of
interferon-non-responsive chronic hepatitis C patients proved14 vol. 61 j 720–722
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ineffective in a clinical trial [14]. It will thus be important to
explore the impact of these different immunosuppressive drugs
on HEV replication in relevant infection model(s) in animals.
HEV replication was recently demonstrated in uPA/SCID mice of
which the diseased liver had been repopulated with human hepa-
tocytes [15]. This, and perhaps other, yet to be developed models,
may be instrumental to demonstrate the differential (anti- and
proviral) effects of the different immunosuppressive drugs. Retro-
spective studies on cohorts of chronic hepatitis E patients may
allow to unveil whether a link exists between the clinical outcome
and the choice of immunosuppressant(s). The low number of
(reported) cases of chronic hepatitis E may complicate such exer-
cise; yet given the recent increase in diagnosed cases, such studies
may become feasible in the future.
One may put different hypotheses forward to explain the anti-
viral defense mechanism mediated by mTOR and downstream
4E-BP1. The protein 4E-BP1 is known to be a translational repres-
sor: by interacting with the essential eukaryotic initiation factor
4E (eIF4E), mRNA translation is inhibited [16]. mTOR is known to
phosphorylate and, thus to deactivate 4E-BP1, thereby releasing
eIF4E which then initiates mRNA translation. More speciﬁcally,
4E-BP1 has important regulatory functions in the interferon
(IFN) response [17]. Cells knocked-out for 4E-BP1 are remarkably
resistant to viral infection because of a decreased threshold for
IFN production [18]. This phenomenon is mediated by increased
mRNA translation of the IFN regulatory factor 7 (Irf7) which is
normally suppressed by 4E-BP1. A similar mechanism may apply
to the observed increase in HEV replication caused by rapamycin
and everolimus. Indeed following inhibition of mTOR activity,
4E-BP1 may not be phosphorylated and thus remains associated
with eIF4E. In this way, translation of Irf7 or other factors would
be inhibited, which may in turn result in a decreased IFN
response and thus overall increased HEV replication. Other
factors may of course be involved as well and alternative mech-
anisms may apply.
Most transplant patients with chronic hepatitis E that do not
clear the virus by reducing immunosuppression are treated with
an extended course of ribavirin [19]. Although this therapy is
mostly effective, cases of treatment failure have been reported
[20]. Moreover, long courses of ribavirin often result in side
effects, including anaemia.Modulation of the immunosuppressive
drug scheme could be a very useful strategy to improve response
rates to ribavirin, decrease the number of patients in need of riba-
virin treatment and shorten the treatment time altogether. Today
potent antiviral drugs are available for the treatment of infections
with herpesviruses, the human immunodeﬁciency virus, the
hepatitis B and C viruses and to a lesser extent inﬂuenza. Viral
polymerase inhibitors (whether targeting DNA polymerases,
reverse transcriptases or RNA-dependent RNA polymerase) have
been shown to be excellent targets for inhibition of viral replica-
tion [21]. Using a combination of highly potent and well tolerated
antivirals, including nucleoside polymerase inhibitors, several
studies recently reported a sustained virological response cure
in >95% of patients chronically infected with the hepatitis C virus
[22]. This latter virus is, akin to HEV, a +ssRNA virus and encodes
for several proteins (including a RNA-dependent RNA polymerase)
that may be good targets for pharmacological inhibition of viral
replication [23]. In fact, it has been shown that some HCV nucle-
oside polymerase inhibitors (in particular the 20C methyl series)
inhibit the replication of yet other +ssRNA viruses including, but
not limited to ﬂaviviruses, enteroviruses and noroviruses [24]. ItJournal of Hepatology 201remains to be studiedwhether (some of the) HCV nucleoside poly-
merase inhibitors that have, or will reach the market, also inhibit
HEV replication. In such a case, they may be used (even off-label)
either alone, or in combination with ribavirin, for the control of
HEV infections. If such combination treatment would be sufﬁ-
ciently potent, there may no longer be a need to reduce immuno-
suppression to control chronic HEV infection in immunodeﬁcient
patients.
In conclusion, the work by Zhou and colleagues reported in
the current issue highlights the potential importance of choosing
the most appropriate immunosuppressant for use in patients
with chronic hepatitis E. Conﬁrmation of the observed in vitro
effects in a suitable animal model for hepatitis E is awaited.
Retrospective analyses (and if possible prospective studies) of
immunosuppressive regimens in chronic hepatitis E patients will
also help to understand the potential effect of immunosuppres-
sive drugs on HEV replication in the infected patient.Financial support
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